Table 3.
Associations between CNGs at 20q11.12-13.21 and clinicopathological factors in HAS
| Parameters | With 20q11.12-13.21 CNG | Without 20q11.12-13.21 CNG | P value |
|---|---|---|---|
| Sex | |||
| Male | 9 (90.0%) | 9 (81.8%) | 0.538 |
| Female | 1 (10.0%) | 2 (18.2%) | |
| Age (years) | |||
| ≥ 60 | 5 (50.0%) | 6 (54.5%) | 0.590 |
| <60 | 5 (50.0%) | 5 (45.5%) | |
| Primary lesion site | |||
| GEJ | 4 (40.0%) | 3 (30.0%) | 0.500 |
| Non-GEJ | 6 (60.0%) | 7 (70.0%) | |
| Serum AFP level | |||
| >500 ng/ml | 7 (77.8%) | 3/6 (50.0%) | 0.287 |
| < 500 ng/ml | 2 (22.2%) | 3 (50.0%) | |
| HAS cell component | |||
| ≥ 50% | 7 (70.0%) | 6 (54.5%) | 0.392 |
| < 50% | 3 (30.0%) | 5 (45.5%) | |
| Lauren subtype | |||
| Intestinal | 7 (70.0%) | 8 (80.0%) | 0.500 |
| Diffuse | 3 (30.0%) | 2 (20.0%) | |
| Pathological stage | |||
| 1-2 | 4 (40.0%) | 5 (45.5%) | 0.575 |
| 3-4 | 6 (60.0%) | 6 (54.5%) | |
| Vascular tumour thrombus | |||
| Yes | 10 (100%) | 8 (72.7%) | 0.124 |
| No | 0 (0%) | 3 (27.3%) | |
| Nerve infiltration | |||
| Yes | 7 (87.5%) | 6 (60.0%) | 0.225 |
| No | 1 (12.5%) | 4 (40.0%) | |
| Liver metastasis | |||
| Yes | 3 (33.3%) | 2 (20.0%) | 0.444 |
| No | 6 (66.7%) | 8 (80.0%) | |